Post-Conference Perspectives: Recent Advances in the Management of Chronic GvHD - Episode 8

Future Directions in Chronic GvHD

,

Dr. Chaudhary and Dr. Merin discuss potential areas for exploration and unmet needs in the chronic GvHD treatment landscape.

EP. 1: The Chronic GvHD Landscape: Risk Factors and Diagnosis
EP. 2: First-line Treatment for Patients with Chronic GvHD
EP. 3: Defining and Managing Steroid Refractory Chronic GvHD
EP. 4: Role of Ruxolitinib in Steroid-Refractory Chronic GvHD
EP. 5: Understanding Mechanisms of Action: Ruxolitinib, Ibrutinib, and Belumosudil
EP. 6: Key Efficacy Data of Ibrutinib and Belumosudil in Steroid-Refractory Chronic GvHD Patients
EP. 7: Real World Data on the Use of Ruxolitinib and Treatment Selection in chronic GvHD
Now Viewing
EP. 8: Future Directions in Chronic GvHD

Related Content:

Post-Conference Perspectives: Recent Advances in the Management of Chronic GvHDCedars-Sinai CancerUSC Norris Comprehensive Cancer CenterHematologic Oncology
Dr Freedland on Implications of Treatment Suspension on HRQOL in High-Risk nmHSPC
Dr Erba on the Safety of Quizartinib By Treatment Phase and Age in FLT3-ITD–positive AML
Dr Bansal on Outpatient Administration With Axi-Cel and Brexu-Cel in R/R NHL